Pre-Clinical Validation and Translation of a Novel Anti-Fibrotic

一些著名的纤维化研究人员估计，1:2的死亡率是由纤维化相关并发症引起的。原发性纤维化疾病是特发性肺纤维化（IPF）：其特征是肺结构改变和呼吸表面积减少，导致肺间质细胞外基质沉积增加。目前的治疗主要是限制进展和治疗症状，而不是治疗疾病或潜在的原因。药物治疗（Esbriet, Ofev）有明显的副作用，只能减缓疾病进展。因此，需要新的抗纤维化药物对维持人类健康和预防过早死亡至关重要。如果忽视日益增长的老龄化人口和纤维化等疾病的结合，将成为一场严重的公共卫生危机。成功的项目交付将改善生活质量，使受影响的人能够继续工作，从而改善社会和经济成果（生产力和医疗保健成本）。

Several prominent researchers in fibrosis have estimated that 1:2 deaths are caused by complications associated with fibrosis. The prototype fibrotic disease is Idiopathic Pulmonary Fibrosis (IPF): characterised by altered lung architecture and loss of respiratory surface area leading to increased deposition of extracellular matrix in the lung interstitium.Current treatments are primarily to limit progression and treat symptoms rather than treat the disease or underlying causes. Pharmaceutical therapies (Esbriet, Ofev) have significant side-effects and only act to slow disease progression.The need for new anti-fibrotic medication is therefore of paramount importance in sustaining human health and preventing premature deaths.If left ignored the combination of a growing aged population and diseases, such as fibrosis, will become a crippling public health crisis. Successful project delivery will improve quality of life and enable those affected to continue to work, thereby improving social and economic outcomes (productivity and healthcare costs).